Cansino (688185) announced on the evening of April 29 that it plans to sign a “Product Transfer and Technology License Agreement” with Shanghai Shangyao Cansino Biopharmaceutical Co., Ltd. (“Shangyao Cansino”), agreeing that the company will transfer the global commercialization rights of the recombinant Ebola virus disease vaccine (adenovirus vector) (“AD5-eBoV”) and transferred products to Shangyao Cansino, and will also reach commercial cooperation through licensing, so that Shanghai Pharmaceutical Cansino can enjoy the right to use the licensed technology related to the transferred product on a global scale. Since approval, the transferred products have not generated sales revenue. The company disclosed its quarterly report on the same day. Net profit for the first quarter of 2024 was a loss of 170 million yuan.
康希诺：拟与上药康希诺签署产品转让与技术许可协议
Cansino: Plans to sign a product transfer and technology licensing agreement with Shanghai Pharmaceutical Cansino
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.